Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 2 · 33.3%High 0 · 0%

Overall survivalÂ · hormone‐sensitive prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · hormone‐sensitive prostate cancer

Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
RR 0.8 [0.62, 1.05]
9 studies · 2750 participants
Low

Quality of life · hormone‐sensitive prostate cancer

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 2887 participants
Moderate

Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · hormone‐sensitive prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cardiovascular events · hormone‐sensitive prostate cancer

It is very uncertain whether degarelix changes cardiovascular events compared with standard androgen suppression therapy (very low certainty).

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
RR 0.15 [0.04, 0.61]
1 study · 80 participants
Very low

Injection site pain · hormone‐sensitive prostate cancer

Degarelix probably leads to higher injection site pain compared with standard androgen suppression therapy (moderate certainty).

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
RR 15.68 [7.41, 33.17]
8 studies · 2670 participants
Moderate